Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

SWITCH: Apixaban mot K-vitamin i HM3

2 november 2026 uppdaterad av: Nir Uriel, Columbia University

SWITCH-studien: En randomiserad kontrollerad studie av apixaban jämfört med K-vitaminantagonister hos patienter med HeartMate 3 vänsterkammarassistansdon

This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced heart failure who are chronically supported by a HeartMate 3 Left Ventricular Assist Device for 3 months.

Studieöversikt

Detaljerad beskrivning

Heart failure is a global epidemic, and Left Ventricular Assist Devices (LVADs) - particularly the HeartMate 3 (HM3) - are increasingly used due to their survival benefit over medical therapy. Despite advances, hemocompatibility-related adverse events (HRAEs) like thrombosis and bleeding remain significant causes of morbidity and mortality.

Direct Oral Anticoagulants (DOACs) have shown superiority over warfarin in heart failure patients, with lower rates of embolic and intracranial bleeding. Reduced-dose DOACs also appear to reduce major bleeding without increasing thrombotic risk. However, data on their use in LVAD patients is limited, consisting mainly of case reports, small series, retrospective analyses, and a few small randomized clinical trials.

Some reports suggest apixaban may reduce bleeding in high-risk LVAD patients, though cases of pump thrombosis and stroke have occurred. Early studies comparing DOACs to warfarin in patients with HeartMate II (HMII), HeartWare™ HVAD™ System, and The Abbott HeartMate 3 (HM3) show no significant differences in outcomes, with a trend toward less bleeding with apixaban. Two small randomized clinical trials in HM3 patients (The DOAC LVAD Study and The DOT-HM3 Study) found similar results.

This prospective, randomized, controlled, non-inferiority trial will evaluate the safety and efficacy of apixaban versus vitamin K antagonists in HM3 patients more than 3 months post-implant.

Studietyp

Interventionell

Inskrivning (Beräknad)

460

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • New York
      • New York, New York, Förenta staterna, 10032
        • Rekrytering
        • Columbia University Irving Medical Center
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 80 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Participants will have HeartMate3 LVAD implanted > 3 months before enrollment
  • ≥ 18 years old
  • Treated with WARFARIN SODIUM
  • Participant must provide written informed consent prior to any clinical investigation related procedure
  • In female participants of childbearing capability, not currently pregnant and on appropriate contraception

Exclusion Criteria:

  • Participation in any other clinical investigation(s) involving a Mechanical Circulatory Support (MCS) device, or interventional investigation(s) likely to confound study results or affect study outcome
  • Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
  • Known allergy to Apixaban
  • Bridge to transplant
  • Severe renal dysfunction Estimated Glomerular Filtration Rate (eGFR) <20
  • History of major bleeding event with subsequent reduction of INR goal to < 1.8
  • Apixaban dose reduction criteria (Age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg/dL)
  • Aortic root thrombus

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Warfarin

Participants will take warfarin, dose titrated for an INR >= 1.8

Warfarin dose titrated for an International Normalized Ratio (INR) >= 1.8

Andra namn:
  • COUMADIN
  • warfarinnatrium
Experimentell: Apixaban

Participants wil take apixaban 5 mg bid

Apixaban 5 mg bid (twice a day)

Andra namn:
  • Eliquis

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Survival free of major hemocompatibility related adverse event
Tidsram: 12 months

Major Hemocompatibility Related Adverse Event: Stroke, Pump Thrombosis, major non surgical Bleeding (moderate or severe), Arterial Peripheral Thromboembolism. Rates will be compared between study groups.

12 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Non-surgical Major Hemorrhagic Events
Tidsram: 12 months

Rates will be compared between study groups.

12 months
Non-surgical Major Thrombotic Events
Tidsram: 12 months

Rates will be compared between study groups.

12 months
Survival
Tidsram: 12 months

Rates will be compared between study groups.

12 months
Stroke Rates
Tidsram: 12 months

Rates will be compared between study groups.

12 months
Pump Thrombosis Rates
Tidsram: 12 months

Rates will be compared between study groups.

12 months
Bleeding Rates
Tidsram: 12 months

Rates will be compared between study groups.

12 months
Rates of listing for Heart Transplant
Tidsram: 12 months

Rates will be compared between study groups.

12 months

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Apixabannivåer hos patienter som drabbats av biverkning
Tidsram: 12 månader
12 månader
Patient functional status
Tidsram: 12 months

Association between anticoagulant regimen and New York Heart Association (NYHA) Functional Classification (FC) will be compared between groups. Scores range I through IV, with higher scores indicating worse outcome.

12 months
Patient QOL
Tidsram: 12 months

Kansas City Cardiomyopathy Questionnaire (KCCQ) 12 scores will be compared between groups. Scores range 1-100, with higher scores indicating better health status.

12 months
LVAD device speed
Tidsram: 12 months

LVAD speed (mean, SD) of LVAD will be compared between study groups. Speed ranges 4500-6000 RPM.

12 months
LVAD device flow
Tidsram: 12 months

LVAD flow (mean, SD) of LVAD will be compared between study groups. Flow ranges 3-6 L/min.

12 months
LVAD device pulsatility index
Tidsram: 12 months

LVAD pulsatility index (PI) will be compared between study groups. PI ranges 1-4 (no units).

12 months
LVAD device power
Tidsram: 12 months

LVAD power (mean, SD) will be compared between study groups. Power ranges 3-7 W.

12 months
Right atrial pressure
Tidsram: 12 months

Right atrial (RA) pressure (mean, SD) will be compared between study groups. RA ranges 0-20 mmHg.

12 months
Right ventricular systolic pressure
Tidsram: 12 months

Right ventricular (RV) systolic pressure (mean, SD) will be compared between study groups. RV systolic pressure ranges 0-100 mmHg.

12 months
Right ventricular diastolic pressure
Tidsram: 12 months

Right ventricular (RV) diastolic pressure (mean, SD) will be compared between study groups. RV diastolic pressure ranges 0-50 mmHg.

12 months
Pulmonary artery systolic pressure
Tidsram: 12 months

Pulmonary artery (PA) systolic pressure (mean, SD) will be compared between study groups. PA systolic pressure ranges 0-100 mmHg.

12 months
Pulmonary artery diastolic pressure
Tidsram: 12 months

Pulmonary artery (PA) diastolic pressure (mean, SD) will be compared between study groups. PA diastolic pressure ranges 0-50 mmHg.

12 months
Pulmonary artery mean pressure
Tidsram: 12 months

Pulmonary artery (PA) mean pressure (mean, SD) will be compared between study groups. PA mean pressure ranges 0-50 mmHg.

12 months
Pulmonary capillary wedge pressure
Tidsram: 12 months

Pulmonary capillary wedge pressure (PCWP, mean, SD) will be compared between study groups. PCWP ranges 0-50 mmHg.

12 months
Cardiac output
Tidsram: 12 months

Cardiac output (CO, mean, SD) will be compared between study groups. CO ranges 3-10 L/min.

12 months
Invasive hemodynamics
Tidsram: 12 months

Cardiac index (CI, mean, SD) will be compared between study groups. CI ranges 2.5-4 L/min/m^2.

12 months
Drive line infection rates
Tidsram: 12 months

Rate of drive line infections will be compared between study groups.

12 months
VAD coordinator time
Tidsram: 12 months

Means will be compared between study groups.

12 months
Laboratory monitoring
Tidsram: 12 months

A quantitative comparison of performed laboratory tests to monitor anticoagulation between groups (counts)

12 months
Days hospitalized
Tidsram: 12 months

Means will be compared between study groups.

12 months
Caregiver burden
Tidsram: 12 months

Self assessed caregiver burden will be collected using the validated The Oberst Caregiving Burden Scale (OCBS), and compared between study groups. Scores range 15-75, with higher scores indicating higher levels of caregiving burden (more time spent or greater difficulty).

12 months
Time in therapeutic range in the warfarin sodium group
Tidsram: 12 months

Means, as well as rates above 70%, will be compared between study groups.

12 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Nir Uriel, MD, New York Presbyterian / Columbia University Medical Center

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

15 oktober 2026

Primärt slutförande (Beräknad)

1 augusti 2029

Avslutad studie (Beräknad)

1 oktober 2029

Studieregistreringsdatum

Först inskickad

24 februari 2026

Först inskickad som uppfyllde QC-kriterierna

11 mars 2026

Första postat (Faktisk)

13 mars 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

4 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera